BIOGEN INC. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
BIOGEN INC. (BIIB) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 3-month period ending 2011-06-30, per its 10-Q filed 2011-07-26.
Discontinued › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2011-07-26
- BIOGEN INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2011-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- BIOGEN INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2010-09-30 was 900.00K shares, a 50.00% increase year-over-year.
- BIOGEN INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2010-06-30 was 800.00K shares, a 14.29% increase year-over-year.
- BIOGEN INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2009-09-30 was 600.00K shares.
- BIOGEN INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2010 was 900.00K shares, a 50.00% increase from fiscal 2009.
- BIOGEN INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2009 was 600.00K shares, a 53.85% decline from fiscal 2008.
- BIOGEN INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2008 was 1.30M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|---|
| 2011-06-30 | 0.00 shares 10-Q · filed 2011-07-26 | ||||
| 2010-12-31 | 900.00K shares 10-K · filed 2011-02-04 | ||||
| 2010-09-30 | 900.00K shares 10-Q · filed 2010-10-26 | 900.00K shares 10-Q · filed 2010-10-26 | |||
| 2010-06-30 | 800.00K shares 10-Q · filed 2010-07-20 | 0.00 shares 10-Q · filed 2011-07-26 | 900.00K shares 10-Q · filed 2010-07-20 | ||
| 2009-12-31 | 600.00K shares 10-K · filed 2011-02-04 | ||||
| 2009-09-30 | 600.00K shares 10-Q · filed 2010-10-26 | 700.00K shares 10-Q · filed 2010-10-26 | |||
| 2009-06-30 | 700.00K shares 10-Q · filed 2010-07-20 | 700.00K shares 10-Q · filed 2010-07-20 | |||
| 2008-12-31 | 1.30M shares 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |